For the induction of final follicular maturation and early luteinisation after stimulation of follicular growth，and for induction of ovulation and luteinisation in anovulatory or oligoovulatory patients after stimulation of follicular growth

Ovidrel is a medicinal product of chorionic gonadotropin produced by recombinant DNA techniques. It shares the amino acid sequence with urinary hCG. Chorionic gonadotropin binds to the LH/hCG receptor of the granulose and theca cells of the ovarian to effect these changes in the absence of an endogenous LH surge.

Following subcutaneous administration, choriogonadotropin alfa is eliminated from the body with a terminal half-life of about 30 hours, and the absolute bioavailability is about 40 %.

Tumours of the hypothalamus and pituitary gland; hypersensitivity to the active substance or to any of the excipients; pvarian enlargement or cyst of undetermined origin; gynaecological haemorrhages of unknown aetiology; ovarian, uterine or mammary carcinoma; pregnancy; primary ovarian failure; uncontrolled thyroid or adrenal dysfunction

X

Infant risk cannot be ruled out

Local reaction/pain at injection site, headache, tiredness, vomiting/nausea, abdominal pain, mild or moderate ovarian hyperstimulation syndrome

For subcutaneous use ONLY! One vial of Ovidrel (250 micrograms) is administered 24 to 48 hours after the last administration of an FSH- or hMG preparation or after optimal stimulation of follicular growth is achieved

vial may be stored refrigerated or at room temperature 2-25℃. Protect from light.